Phase II trial: uPAR PET/CT and FDG PET/MRI for determining lymph node metastases in patients with bladder cancer

Registry ID
EUCTR2016-001026-33
Source registry
EUCTR
Status
Completed
Phase
PHASE2
Sponsor
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET
Start date
2016-06-08
Completion date
2017-12-04
Last update
2026-08-16

Conditions

Summary

The sensitivity and specificity of 68Ga-NOTA-AE105 PET/CT and FDG PET/MR for detection of regional lymph node metastases will be tested by observer-blinded readings (two separate teams) and compared to diagnostic performance of conventional preoperative procedure. The reference test will be histopathology of lymph nodes obtained by operative lymph node dissection based on 6 regions. The suspected lymph nodes will be assigned to 6 regions based on the images. During the following operation the lymph nodes will be removed and analysed in each of these regions.

Locations

View on source registry